CytoDyn Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Dr. Pourhassan and Mobeen Syed, M.D., M.S. will discuss the Company’s multi-pathway to exploring the many potential opportunities for leronlimab, including COVID-19

CytoDyn’s CEO Dr. Pourhassan to Appear on DrBeen Webcast Tomorrow July 18, 2020

VANCOUVER, Washington, July  15, 2020  (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it recently filed a comprehensive listing application package with The Nasdaq Stock Market to request an uplisting of the Company’s common stock.  The Company believes it satisfies the initial listing requirements for The Nasdaq Capital Market®.

CytoDyn Files Application with Nasdaq for Uplist

BioCryst Pharmaceuticals

BioNTech SE

Biosig Technologies Inc

Eiger BioPharmaceuticals

Gilead Sciences

Immunic Inc

Pfizer

Regeneron Pharmaceuticals

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

Shares of CytoDyn Inc. CYDY, -37.52% fell 9.4% in trading on Monday after the company said it received a refusal to file letter from the Food and Drug Administration for its experimental HIV drug leronlimab.

CytoDyn's stock falls after hitting roadblock in FDA application for investigational HIV drug

Update on COVID-19: CytoDyn is planning to lock and unblind the Phase 2 COVID-19 trial data later this week. Periodic safety review by Data Safety Monitoring Committee (DSMC) for ongoing Phase 3 study (severe/critical population) is planned for next week. Both results to be announced in July

Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required.

CytoDyn: Bears Bring Out Their Champion To Take On The Army Of Bulls

Change in Location of the Special Meeting to be held on July 22, 2020 

Important Update for CytoDyn Special Meeting of Stockholders

Results of preclinical study presented today in oral presentation at the 23rd International AIDS Conference (AIDS 2020) 

CytoDyn’s Leronlimab Prevents Transmission of SHIV in Macaque Study

Antivirals Rather Than Vaccines For COVID-19

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of CytoDyn’s ongoing clinical trials and FDA approval

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

Money is made at the extremes, and CytoDyn shareholders saw a day of extremes when the fireworks arrived early on June 30, 2020.

CytoDyn's Rude Interruption

VANCOUVER, Washington, July  02, 2020  (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the public release of the animation for leronlimab in immuno-oncology. Click  here  to view the animation.

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.

CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study

VANCOUVER, Washington, June  29, 2020  (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Company and the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals of Mexico (NIH) have entered into a Memorandum of Understanding (MOU) to conduct a COVID-19 clinical trial with leronlimab for severe and critically ill patients, with the potential to collaborate on additional COVID-19 trials. The NIH of Mexico is an organization that coordinates the main institutions of medical care and public research in the country. 

CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients

Don't Forget Cytodyn's Other Prospects

On June 11, the company provided a comprehensive update via a CC.

Cytodyn And COVID-19: The Endgame Is On

Preclinical results demonstrated leronlimab effectively inhibited fatty liver development

CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH

VANCOUVER, Washington, June  11, 2020  (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Company has met its 75 patient enrollment for its Phase 2 clinical trial entitled “Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19.” 

CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication – Primary End Point Announcement Is Next

PDUFA date could be set by the FDA on July 10

CytoDyn Receives BLA Acknowledgment Letter From the FDA

Athersys

Chimerix

CytoSorbents

Mesoblast

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

COVID-19 Therapeutics: The Leading Contenders

Adaptive Biotechnologies

Amgen

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

GlaxoSmithKline

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

CytoDyn: Matching Leronlimab Up Against Other COVID-19 Therapeutics

CytoDyn: Managing My Position Following BLA Submission And COVID-19 Progress

News for CytoDyn Inc. Stock (CYDY)